Skip to content

Depression: all studies

Page 120 of 1,034: studies 1,191 to 1,200 of 10,336, newest first. Back to the depression overview

Research

Rapid Antidepressant and Antisuicidal Effects of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression With or Without Low-Grade Inflammation.

Pharmacopsychiatry December 20, 2024 Mu-Hong Chen, Tung-Ping Su, Wei-Chen Lin et al. 1 citation

Low-grade inflammation (LGI) contributes to resistance against traditional antidepressants. However, whether the antidepressant and antisuicidal effects of ketamine on patients with treatment-resistant depression (TRD) differ between those with LGI and those without LGI remains unknown.This study included 167 patients with TRD, among whom 46 had LGI and 121 did not have LGI. The patients...

DOI: 10.1055/a-2499-7207 (opens in new tab) Full text (opens in new tab) Depression treatment Ketamine therapy Mental health Antidepressants +1

Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment.

International Journal of Molecular Sciences December 20, 2024 Zuzanna Antos, Xawery Żukow, Laura Bursztynowicz et al. 14 citations

The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, its precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine's molecular actions. Ketamine primarily works...

HIV Patients' Mindfulness Moderates How Death Anxiety and Depression Impact Life Quality.

OMEGA - Journal of Death and Dying December 18, 2024 Chinenye Joseph Aliche, Erhabor Sunday Idemudia 5 citations

Many people living with HIV (PLWH) experience death anxiety and depression, which may impact negatively on their health-related quality of life (HRQoL). Mindfulness is a psychological resource that protects against death anxiety and depression and promotes HRQoL. Although a direct association among these variables exist, little is known about their interactive effect. This study examined the...

Treatment Advances in Perinatal Depression: Innovations and Promising Approaches.

Journal of Clinical Medicine December 18, 2024 Kathleen Kendall-Tackett 2 citations

Background/Objectives: Psychotherapy and antidepressants are the standard treatment for depression during pregnancy or postpartum. However, several new treatments for depression represent major advances and paradigm changes. This commentary highlights some innovative treatment options that are on the horizon. Most of these modalities are promising, and most are non-invasive. Many of these...

Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature

Journal of Psychopharmacology December 17, 2024 Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena 1 citation

Background: Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. Aim: This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. Methods: A...

The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial.

Journal of Affective Disorders December 15, 2024 Rodrigo Machado‐Vieira, Gregory H Jones, Alan C. Courtes et al.

Fatigue is a multidimensional condition that may overlap with depression. Initial studies found that fatigue responds in only a limited way to standard monoaminergic antidepressants and mood stabilizers but does respond positively to intravenous (IV) racemic (R,S)-ketamine (ketamine). However, IV ketamine's use is limited by cost and access barriers. To date, no study has evaluated intranasal...

Effects of ketamine on metabolic parameters in depressive disorders: A systematic review.

Journal of Affective Disorders December 15, 2024 Sabrina Wong, Gia Han Le, Rodrigo B. Mansur et al. 3 citations

Persons with Major Depressive Disorder (MDD), notably treatment-resistant depression (TRD), are differentially affected by type 2 diabetes mellitus and associated morbidity. Ketamine is highly efficacious in the treatment of adults living with MDD, notably TRD. Herein, we sought to determine the effect of ketamine on metabolic parameters in animal stress paradigms and human studies. We...

DOI: 10.1016/j.jad.2024.08.208 (opens in new tab) Full text (opens in new tab) Glucose homeostasis Insulin Treatment-resistant depression trd Ketamine therapy +4

Interventional approaches to treatment resistant depression (DTR) in children and adolescents: A systematic review and meta-analysis.

Journal of Affective Disorders December 15, 2024 Ethan Faries, Landon A Mabe, Ronald L Franzen et al. 13 citations

Major depressive disorder (MDD) is highly prevalent in youth. Conventional treatment paradigms primarily involve selective serotonin reuptake inhibitors (SSRIs) and psychotherapy, yet a significant proportion of this population exhibits treatment-resistant depression (TRD). In adults, interventional therapies like Electroconvulsive Therapy (ECT), repetitive Transcranial Magnetic Stimulation...

Effects of arketamine on depression-like behaviors and demyelination in mice exposed to chronic restrain stress: A role of transforming growth factor-β1.

Journal of Affective Disorders December 15, 2024 Dan Xu, Guilin Liu, Mingming Zhao et al. 21 citations

Chronic restrain stress (CRS) induces depression-like behaviors and demyelination in the brain; however, the relationship between these depression-like behaviors and demyelination remains unclear. Arketamine, the (R)-enantiomer of ketamine, has shown rapid antidepressant-like effects in CRS-exposed mice. We examined whether arketamine can improve both depression-like behaviors and demyelination...

Treatment Expectancies and Psilocybin vs Escitalopram for Depression

JAMA Psychiatry December 10, 2024 Ethan G. Dutcher, Andrew D. Krystal 5 citations

This secondary analysis of a randomized clinical trial examines the association between treatment expectancies and the relative efficacy of psilocybin compared with escitalopram for major depressive disorder.